U.S. Sens. Katie Britt (R-Montgomery) and Tommy Tuberville (R-Auburn) joined other Senate Republicans in calling on U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. and U.S. Food and Drug Administration (FDA) commissioner Dr. Martin Makary to reconsider the recent approval of a new generic abortion pill by the FDA.
The Senators urged HHS and FDA to review the decision to approve a generic version of mifepristone — currently the leading drug used to perform chemical abortions. Not only is this drug deadly for preborn babies and a serious health risk for expectant mothers, but the decision also runs afoul of states with pro-life laws on the books.
“We commend your recent statements acknowledging the data discrepancies surrounding abortion pill safety and your commitment to reviewing the science. We are also encouraged by HHS’s recent announcement that it will review prior Risk Evaluation and Mitigation Strategies approvals given the recent studies raising concerns about the drug’s safety. Given this commitment, however, we are deeply concerned about the FDA’s approval of a new generic version of mifepristone,” Britt and Tuberville said in the letter.
“While we recognize the FDA’s statutory responsibility in evaluating drug applications, the timing of this approval appears inconsistent with the comprehensive safety reassessment your agencies have prioritized," they added. "Out of respect for this important review, and with full confidence in your dedication to protecting women’s health, states’ rights, and unborn life, we urge you to take decisive action to reevaluate whether this generic version of mifepristone is suitable to enter the market."
To connect with the author of this story or to comment, email [email protected].
Don't miss out! Subscribe to our newsletter and get our top stories every weekday morning.
